siRNA halts ccRCC tumor growth in phase I trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In a phase I clinical trial led by UT Southwestern Medical Center, a short interfering RNA drug directed to tumor cells effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging an attack from natural killer cells in an animal model, a study led by UT Southwestern Medical Center researchers shows. The findings, published in the Journal for ImmunoTherapy of Cancer, could lead to new types of immunotherapy that rely on this novel strategy.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login